These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 32777582)
1. Falciparum malaria-induced secondary hemophagocytic lymphohistiocytosis successfully treated with ruxolitinib. Fuchs A; Orth HM; Germing U; Kondakci M; Holtfreter M; Feldt T; Jensen BE; Häussinger D Int J Infect Dis; 2020 Nov; 100():382-385. PubMed ID: 32777582 [TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series. Hansen S; Alduaij W; Biggs CM; Belga S; Luecke K; Merkeley H; Chen LYC Eur J Haematol; 2021 May; 106(5):654-661. PubMed ID: 33523540 [TBL] [Abstract][Full Text] [Related]
3. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Meyer LK; Verbist KC; Albeituni S; Scull BP; Bassett RC; Stroh AN; Tillman H; Allen CE; Hermiston ML; Nichols KE Blood; 2020 Aug; 136(6):657-668. PubMed ID: 32530039 [TBL] [Abstract][Full Text] [Related]
4. Combined IL-6 and JAK/STAT inhibition therapy in COVID-19-related sHLH, potential game changer. Portsmore S; Tran Nguyen TN; Beacham E; Neelakantan P Br J Haematol; 2020 Aug; 190(4):525-528. PubMed ID: 32584421 [No Abstract] [Full Text] [Related]
5. Ruxolitinib as first-line therapy in secondary hemophagocytic lymphohistiocytosis and HIV infection. Gálvez Acosta S; Javalera Rincón M Int J Hematol; 2020 Sep; 112(3):418-421. PubMed ID: 32285358 [TBL] [Abstract][Full Text] [Related]
6. Ruxolitinib for the treatment of lymphoma-associated hemophagocytic lymphohistiocytosis: A cautionary tale. Trantham T; Auten J; Muluneh B; Van Deventer H J Oncol Pharm Pract; 2020 Jun; 26(4):1005-1008. PubMed ID: 31575356 [TBL] [Abstract][Full Text] [Related]
7. Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis. Keenan C; Nichols KE; Albeituni S Front Immunol; 2021; 12():614704. PubMed ID: 33664745 [TBL] [Abstract][Full Text] [Related]
8. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Das R; Guan P; Sprague L; Verbist K; Tedrick P; An QA; Cheng C; Kurachi M; Levine R; Wherry EJ; Canna SW; Behrens EM; Nichols KE Blood; 2016 Mar; 127(13):1666-75. PubMed ID: 26825707 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Maschalidi S; Sepulveda FE; Garrigue A; Fischer A; de Saint Basile G Blood; 2016 Jul; 128(1):60-71. PubMed ID: 27222478 [TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib-loaded cytokine nanosponge alleviated the cytokine storm and dampened macrophage overactivation for the treatment of hemophagocytic lymphohistiocytosis. Wang H; Wang Y; Liu H; Li X; Sun C; Pang Z; Zhang B; Hu Y Int J Pharm; 2024 May; 657():124127. PubMed ID: 38621611 [TBL] [Abstract][Full Text] [Related]
11. Etoposide combined with ruxolitinib for refractory hemophagocytic lymphohistiocytosis during pregnancy: a case report and literature review. Wang S; Wu J; Jing X; Zhang Y; Tang H; Wu J Hematology; 2019 Dec; 24(1):751-756. PubMed ID: 33138732 [TBL] [Abstract][Full Text] [Related]
12. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis: First case report. Sin JH; Zangardi ML Hematol Oncol Stem Cell Ther; 2019 Sep; 12(3):166-170. PubMed ID: 28834694 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis. Keenan C; Albeituni S; Oak N; Stroh A; Tillman HS; Wang Y; Freeman BB; Alemán-Arteaga S; Meyer LK; Woods R; Verbist KC; Zhou Y; Cheng C; Nichols KE Blood; 2024 Jun; 143(23):2386-2400. PubMed ID: 38446698 [TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis. Ono R; Ashiarai M; Hirabayashi S; Mizuki K; Hosoya Y; Yoshihara H; Ohtake J; Mori S; Manabe A; Hasegawa D Int J Hematol; 2021 Feb; 113(2):297-301. PubMed ID: 32979171 [TBL] [Abstract][Full Text] [Related]
15. Short-term effectiveness of ruxolitinib in the treatment of recurrent or refractory hemophagocytic lymphohistiocytosis in children. Wei A; Ma H; Li Z; Zhang L; Zhang Q; Wang D; Lian H; Zhang R; Wang T Int J Hematol; 2020 Oct; 112(4):568-576. PubMed ID: 32666469 [TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis. Jianguo L; Zhixuan Z; Rong L; Xiaodong S Pediatrics; 2020 Aug; 146(2):. PubMed ID: 32680878 [TBL] [Abstract][Full Text] [Related]
17. CLINICAL case report: falciparum malaria with hemophagocytic syndrome. Ohnishi K; Mitsui K; Komiya N; Iwasaki N; Akashi A; Hamabe Y Am J Trop Med Hyg; 2007 Jun; 76(6):1016-8. PubMed ID: 17556603 [TBL] [Abstract][Full Text] [Related]
18. Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS. Liu X; Zhu X; Zhou X; Xie Y; Xiang D; Wan Z; Huang Y; Zhu B Front Immunol; 2022; 13():1012643. PubMed ID: 36263041 [TBL] [Abstract][Full Text] [Related]
19. Hemophagocytic syndrome associated with Plasmodium falciparum infection. Vinoth PN; Thomas KA; Selvan SM; Suman DF; Scott JX Indian J Pathol Microbiol; 2011; 54(3):594-6. PubMed ID: 21934231 [TBL] [Abstract][Full Text] [Related]
20. Alleviating the storm: ruxolitinib in HLH. La Rosée P Blood; 2016 Mar; 127(13):1626-7. PubMed ID: 27034417 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]